2Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed[J]. Semin Oncol, 2002, 29(6Suppl 18) : 3-17.
3Shih C, Chen V J, Gossett LS, et al. LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folaterequiring enzymes [J], Cancer Res, 1997, 57 (6) : 1116-1123.
4Taylor EC, Liu B, Process for the preparation of pyrrolo [2,3-d]pyrimidines [P], US: 6066732, 2000-05-23. (CA 2000,132: 166253).
5Taylor EC, Liu B. A simple and concise synthesis of LY231514(MTA) [J]. Tetrahedron Lett, 1999, 40: 4023-4026.
6Smith MB, March J, Advanced Organic Chemistry [M], New York: John Wiley & Sons, 2001, 1178-1179.
7Taylor EC, Gillespie P, Patel M. Novel 5-desmethylene analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid as potential anticancer agents [J]. J Org Chem, 1992, 57:3218-3225.
8Worrall DE, Marvel CS, Lycan WH. Organic Syntheses [M].Vol 9, New York: John Wiley & Sons, 1929.66-68.
9Barnett CJ, Wilson TM, Kobierski ME. A practical dynthesis of multitargeted sntifolate LY231514 [J]. Org Process Res Dev, 1999, 3: 184-188.
10Taylor EC, Patel HH, Jun JG. A one-step ring transformation/ring annulation approach to pyrrolo [2,3-d] pyrimidines. A new synthesis of the potent DHFR inhibitor TNP-351 [J]. J Org Chem, 1995, 60: 6684-6687.
